Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
incmnsz.mxLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
142
Active
14
Phase 3
10
Total enrollment
18,524
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Melatonin 3 MG Oral | — | — | — | — | — | 1 | |
| Dapagliflozin 10 MG Oral | — | — | — | — | — | 1 |
Next readouts
- 2026-09-30
- 2027-12-22
Top conditions
- Obesity11
- Liver Cirrhosis7
- Metabolic Syndrome5
- Insulin Resistance5
- Cirrhosis5
- Covid194
- Malnutrition4
- Healthy3
Frequently asked questions about Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- How many clinical trials does Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran have on ClinicalTrials.gov?
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran is listed as the lead sponsor on 142 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran's trials are in Phase 3?
- 10 of Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran focus on?
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran's most-studied conditions on ClinicalTrials.gov are Obesity, Liver Cirrhosis, Metabolic Syndrome, Insulin Resistance, Cirrhosis.
- When are Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran's next clinical trial readouts?
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran has 2 upcoming primary-completion readouts tracked here; the soonest is “Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity”, expected around 2026-09-30.